The scientific case linking heavy metal exposure to autism spectrum disorder has strengthened substantially over the past decade. A landmark 2021 study published in JAMA Pediatrics analyzed data from the National Health and Nutrition Examination Survey and found that children in the highest quartile of blood lead levels were significantly more likely to have a parent-reported ASD diagnosis than children in the lowest quartile. The same study documented a dose-response relationship between arsenic exposure and ASD prevalence, providing strong evidence that the association is not coincidental.

The proposed biological mechanisms are well-documented. Inorganic arsenic disrupts the Nrf2 oxidative stress pathway, which is already implicated in ASD pathophysiology in genetically susceptible children. Lead interferes with N-methyl-D-aspartate (NMDA) receptor function, disrupting the glutamate signaling that is critical for synaptic development during the first two years of life — precisely the period when infants are consuming the baby foods at issue. Mercury methylates to form methylmercury, which crosses the blood-brain barrier and accumulates in neurons, disrupting microtubule formation and neuronal migration. The NIH National Institute of Environmental Health Sciences has designated heavy metal neurotoxicity a priority research area and has funded multiple longitudinal cohort studies documenting these associations.

Courts in MDL 3101 have taken the scientific literature seriously. Plaintiffs’ causation experts — including pediatric neurologists and environmental epidemiologists — have survived initial Daubert challenges, with Judge Corley noting that the 2021 Congressional report, combined with the peer-reviewed literature, provides a sufficient basis for a general causation opinion to be presented to a jury. A full Daubert hearing is scheduled for mid-2026, and plaintiffs’ legal team has retained leading scientists in the field of environmental neurotoxicology to testify.